Semmelweis University
🇭🇺Hungary
- Country
- 🇭🇺Hungary
- Ownership
- Private, Subsidiary
- Established
- 1769-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.sote.hu
Clinical Trials
126
Active:16
Completed:55
Trial Phases
6 Phases
Early Phase 1:2
Phase 1:3
Phase 2:4
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (90 trials with phase data)• Click on a phase to view related trials
Not Applicable
61 (67.8%)Phase 4
15 (16.7%)Phase 3
5 (5.6%)Phase 2
4 (4.4%)Phase 1
3 (3.3%)Early Phase 1
2 (2.2%)KInetics of Procalcitonin to Reduce Unnecessary aNtibiotic Use - Comparing Procalcitonin Kinetics-guided Antibiotic Initiation With Using Absolute Procalcitonin Values in Reducing Unnecessary Antibiotic Use in Critically Ill Patients
Not Applicable
Not yet recruiting
- Conditions
- InfectionSepsis
- First Posted Date
- 2025-10-08
- Last Posted Date
- 2025-10-08
- Lead Sponsor
- Semmelweis University
- Target Recruit Count
- 250
- Registration Number
- NCT07211620
- Locations
- 🇭🇺
Saint Margaret's Hospital, Budapest, Hungary
🇭🇺Semmelweis University, Department of Intensive Therapy, Budapest, Hungary
Effect of Theta-burst rTMS Therapy on the Clinical and Cognitive Symptoms of Patients With Therapy Resistant Depression and Response Prediction With Neuroimaging Methods.
Not Applicable
- Conditions
- Transcranial Magnetic Stimulation, RepetitiveDepression - Major Depressive Disorder
- First Posted Date
- 2025-10-03
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- Semmelweis University
- Target Recruit Count
- 54
- Registration Number
- NCT07207239
- Locations
- 🇭🇺
Department of Psychiatry and Psychotherapy, Budapest, Pest County, Hungary
Associations of Autistic Traits and Feeding Difficulties
Recruiting
- Conditions
- Autism Spectrum Disorder (ASD)
- First Posted Date
- 2025-09-23
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- Semmelweis University
- Target Recruit Count
- 600
- Registration Number
- NCT07188870
- Locations
- 🇭🇺
Bethesda Children's Hospital, Budapest, Hungary
Healing of Intrabony Defects Following Treatment With PRF or EMD
Not Applicable
Completed
- Conditions
- Periodontal Bone LossPeriodontal DiseasePlatelet Rich Fibrin
- First Posted Date
- 2025-09-19
- Last Posted Date
- 2025-09-19
- Lead Sponsor
- Semmelweis University
- Target Recruit Count
- 28
- Registration Number
- NCT07183631
- Locations
- 🇭🇺
Semmelweis University, Budapest, Hungary
Adaptation of Pediatric Speech Audiometry Tests Into Other Languages
Recruiting
- Conditions
- Hearing LossScreening
- First Posted Date
- 2025-09-05
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- Semmelweis University
- Target Recruit Count
- 120
- Registration Number
- NCT07156825
- Locations
- 🇭🇺
Semmelweis University, Budapest, Hungary
- Prev
- 1
- 2
- 3
- 4
- 5
- 23
- Next
News
Algernon NeuroScience Launches Phase 2a Trial of DMT for Stroke Recovery with Leading Neurologist
Algernon NeuroScience appoints Dr. Sándor Nardai to lead a groundbreaking Phase 2a clinical trial investigating DMT as a potential stroke recovery treatment, set to begin in Q3 2025.